# NAJM AI ClinicNote — Family Evidence and Multi-Workflow Activation Wave 5

## Completion

`NAJM_FAMILY_EVIDENCE_AND_WAVE5_COMPLETE`

Branch: `beta-family-evidence-and-wave5-v1`  
Baseline branch: `beta-family-evidence-and-wave4-v1`  
Starting HEAD: `63fd7d8339ba99aaf178d91b8bfc1dc0d2b810b9`  
Implementation ending HEAD: `3bcaf1c7`  
Final documentation HEAD: `e3c04d3f` (documentation only; not redeployed)  
Beta URL: https://hosxam.github.io/najm-ai-clinicnote-v2-beta/#/beta  
Deployment workflow: https://github.com/hosxam/najm-ai-clinicnote-v2-beta/actions/runs/30277066368  

## Narrow commits

- `fea78e77` chore(wave5): add family evidence Wave-5 pipeline
- `5a6cbe53` research(wave5): close Wave-4 evidence gaps
- `8c8ac606` research(wave5): acquire targeted family sources
- `295a55ae` data(wave5): build family evidence packs
- `efa1bc53` data(wave5): build workflow evidence packs
- `a9b89f59` feat(wave5): activate completed workflow schemas
- `fa6ff6c` test(wave5): validate activations and regression
- `2a2428a` feat(wave5): add outputs and catalogue metadata
- `3bcaf1c7` fix(wave5): reconcile family pack totals
- `ddeaaa11` docs(wave5): complete Wave-5 report
- `dae94e2f` docs(wave5): note final documentation head
- `e3c04d3f` docs(wave5): clarify documentation-only deployment boundary

## Counts and evidence

- Original workflows: 1,500
- Active usable workflows: 531
- Inactive workflows: 969
- Clinician-facing items: 8,165
- Internal evidence records: 83,332
- Interactive schema fields: 5,785
- Families processed: 12
- Distinct workflow targets: 74
- Activated targets: 74
- Wave 4 distinct inactive baseline recalculated from the final inventory: 1,043
- Wave 4 named gaps closed: `peds-bedwetting-documentation`, `peds-food-allergy-documentation`, `renal-aki-follow-up-after-discharge`, and `renal-hemodialysis-clinic-documentation`
- Source registry: 238 → 242; four newly ingested official sources
- Exclusions: 12
- Mappings/candidates: 0 / 0

The source registry replay has 242 sources, 151 modules (initial plus 150 numbered batches), and zero parity differences. Metadata fingerprint: `e9efd82ddfbeef8bc057271bb8fb8e42ba5745a918e19efc84f023daf676bf1f`. Replay manifest fingerprint: `6efb37d2aa8271aac771781b8c6f185181c07682df0c1f0075b98a22ac2f77f9`.

Recency validation passed under the fixed policy. Basis totals are 25 explicit stronger-date, 3 approved-unknown, 69 weaker-metadata, and 145 access-verification-only. Outcomes include 24 stronger-date current, 3 approved-unknown current, 65 weaker-metadata current, 126 access-verification current, 23 recheck due, and one incomplete-recency source; no unavailable, superseded or expired outcomes.

The Wave 5 artifact contract was independently rechecked after enrichment: all four gap records include their missing critical sections, prior insufficiency, named organisations, exact queries, located/obtained/extracted documents, accepted/rejected source decisions and final coverage; all 12 family records include exclusions, archetypes, prioritisation/reuse scoring method and expected outputs; all 74 target records include scope, archetype, required sources, expected sections and activation feasibility; all 962 added field-provenance records include source organisation/document/URL, exact locator, population/setting qualifiers and transformation explanation. The 433-record manual-defect resolution and closure assertion suites passed. The Wave 4 baseline evidence retained 457 active workflows, 625 reconciled fields, 127 selectable controls and 111 contradiction groups; the four named Wave 5 gap closures are the only intentional state changes.

## Validation

The Wave 5 validator, source ingestion/replay/fingerprint/reproducibility, source recency, final catalogue and route wiring, interactive schema, clinician-facing separation, Advanced mode, item evidence, pack dependencies, merge aliases, retirement, blocked-source, medication safety, safety, data, research claims, source evidence, item provenance, evidence hashes, clinical reproducibility, Quick/Advanced SOAP (531 cases; 1,062 mode cases), all-workflow checks, output safety, research queue, accessibility, performance, compaction, parent Wave 3, dependency graph, candidate evaluation (3,363/3,363 terminal), manual-defect resolution (433 records), manual-defect closure assertions, lint and build all passed. Lint completed with pre-existing warnings only. The historical Wave 4 family validator correctly reports the four named gap records as no longer fail-closed inactive; this is the intentional Wave 5 closure and not a regression.

## Live beta verification

Deployment run `30277066368` succeeded from this Wave 5 branch. The live build displayed `3bcaf1c`. The canonical final manifest and interactive manifest loaded with the counts above; the beta route did not use the obsolete curated-workflows dataset. The four repaired workflows and a neurology, ophthalmology, women’s-health, urology, dermatology, geriatric, critical-care and mental-health representative each opened with Quick, Advanced and evidence panels. Desktop, tablet and mobile checks passed with no horizontal overflow, zero console errors and zero failed non-aborted asset requests. Draft state was cleared between route checks and remained workflow-scoped.

Stable production was not deployed or modified. No main merge, rebase, force-push, signing, approval, mapping, candidate, exclusion, canonical approval, or production public-data action was performed.

## Remaining truthful limitations

Wave 5 activates source-grounded documentation schemas and preserves the existing clinician review and safety caveats. It does not create clinician approvals, mappings or prescribing decisions. Source extraction retains the corpus’s documented structural-access limitations, and all outputs remain documentation drafting only and require clinician review.
